 |
Top 10 Brain Regeneration startups in USA
Updated: May 09, 2024 |
1
Funding: $1.1B
Neurodegenerative diseases are one of the largest medical challenges of our time. Denali Therapeutics is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development.
Neurodegenerative diseases are one of the largest medical challenges of our time. Denali Therapeutics is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development.
2
Funding: $612M
Neumora Therapeutics is pioneering a new era of precision medicines for Brain Diseases
Neumora Therapeutics is pioneering a new era of precision medicines for Brain Diseases
3
Funding: $487.2M
At Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the gut informs our brains about our well-being, metabolism, and nutritional state. The gut-brain axis—the communication highway between our gut and our brain—offers an unprecedented opportunity to access and influence brain centers involved in fundamental human processes. An understanding of the biology mediated by the gut and gut-brain circuits will change the way we think about food, nutrition, and human physiology.
At Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the gut informs our brains about our well-being, metabolism, and nutritional state. The gut-brain axis—the communication highway between our gut and our brain—offers an unprecedented opportunity to access and influence brain centers involved in fundamental human processes. An understanding of the biology mediated by the gut and gut-brain circuits will change the way we think about food, nutrition, and human physiology.
4
Funding: $448.5M
Amylyx Pharmaceutical is a pharmaceutical company that specializes in providing solutions on Alzheimer’s and other diseases of the brain.
Amylyx Pharmaceutical is a pharmaceutical company that specializes in providing solutions on Alzheimer’s and other diseases of the brain.
5
Funding: $409M
Pear Therapeutics develops digital therapies to address a broad range of severe conditions including addiction, schizophrenia, pain, post-traumatic stress disorder, anxiety, depression, and sleep. PEAR’s eFormulationTM platform combines pharmaceutical preparations with user-friendly, customizable, and scientifically validated software applications. PEAR’s patented approach provides better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payors. Pear Therapeutics filed for bankruptcy
Pear Therapeutics develops digital therapies to address a broad range of severe conditions including addiction, schizophrenia, pain, post-traumatic stress disorder, anxiety, depression, and sleep. PEAR’s eFormulationTM platform combines pharmaceutical preparations with user-friendly, customizable, and scientifically validated software applications. PEAR’s patented approach provides better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payors. Pear Therapeutics filed for bankruptcy
6
Funding: $374M
Voyager Therapeutics is a clinical stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS). Gene therapy has the potential to transform the treatment of CNS and other diseases by providing a one-time therapy that dramatically improves patients' lives.
Voyager Therapeutics is a clinical stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS). Gene therapy has the potential to transform the treatment of CNS and other diseases by providing a one-time therapy that dramatically improves patients' lives.
7
Funding: $373.4M
Neuronetics has pioneered and refined the NeuroStar TMS Therapy system. This non-invasive, non-systemic treatment for depression uses a highly focused, pulsed magnetic field to stimulate function in targeted brain regions. NeuroStar TMS Therapy is a safe and effective outpatient procedure, performed in a physician's office with each treatment lasting about 37 minutes daily for four to six weeks.
Neuronetics has pioneered and refined the NeuroStar TMS Therapy system. This non-invasive, non-systemic treatment for depression uses a highly focused, pulsed magnetic field to stimulate function in targeted brain regions. NeuroStar TMS Therapy is a safe and effective outpatient procedure, performed in a physician's office with each treatment lasting about 37 minutes daily for four to six weeks.
8
Funding: $273.9M
Aptinyx Inc. is a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovering proprietary compounds that work through a novel mechanism: modulation of the NMDA receptor to enhance pathways involved with nerve cell communication.
Aptinyx Inc. is a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovering proprietary compounds that work through a novel mechanism: modulation of the NMDA receptor to enhance pathways involved with nerve cell communication.
9
Funding: $269.5M
Alector is a hypothesis-driven, neurology-focused startup that’s pioneering the discovery and development of first-in-class, immuno-modulatory therapies for Alzheimer’s disease and other neurodegenerative disorders. We are combining state-of-the-art antibody technology and recent discoveries in neuro-immunology and human genetics to develop a broad platform of novel therapeutics that harness the immune system to fight dementia and neurodegeneration.
Alector is a hypothesis-driven, neurology-focused startup that’s pioneering the discovery and development of first-in-class, immuno-modulatory therapies for Alzheimer’s disease and other neurodegenerative disorders. We are combining state-of-the-art antibody technology and recent discoveries in neuro-immunology and human genetics to develop a broad platform of novel therapeutics that harness the immune system to fight dementia and neurodegeneration.
10
Funding: $225M
Cortexyme is developing novel treatments for altering the course of Alzheimer's and other degenerative diseases.
Cortexyme is developing novel treatments for altering the course of Alzheimer's and other degenerative diseases.
Ad
Advertise your startup
11
Funding: $221M
Engrail Therapeutics is a developer of medicines to transform the lives of patients with life-limiting diseases of the nervous system.
Engrail Therapeutics is a developer of medicines to transform the lives of patients with life-limiting diseases of the nervous system.
12
Funding: $157.2M
Alzheon is committed to developing innovative medicines for patients suffering from Alzheimer's disease and other neurological and psychiatric disorders. Our Alzheon’s drug development platform which comprises proprietary chemistries, robust clinical efficacy and safety datasets in patients and genetically-defined subpopulations, and the ability to optimize molecules to have the desired therapeutic attributes.
Alzheon is committed to developing innovative medicines for patients suffering from Alzheimer's disease and other neurological and psychiatric disorders. Our Alzheon’s drug development platform which comprises proprietary chemistries, robust clinical efficacy and safety datasets in patients and genetically-defined subpopulations, and the ability to optimize molecules to have the desired therapeutic attributes.
13
Funding: $140M
Capsida develops targeted gene therapies in serious neurodegenerative diseases.
Capsida develops targeted gene therapies in serious neurodegenerative diseases.
14
Funding: $137.4M
Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Yumanity is working to identify and develop new, disease-modifying therapies that address several illnesses with critical unmet medical needs. The initial focus of the company is neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS).
Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Yumanity is working to identify and develop new, disease-modifying therapies that address several illnesses with critical unmet medical needs. The initial focus of the company is neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS).
15
Funding: $134.1M
We use genomic data to find better drugs, faster. We find new cures for brain diseases 1000X more cheaply and quickly using our proven network algorithms.
We use genomic data to find better drugs, faster. We find new cures for brain diseases 1000X more cheaply and quickly using our proven network algorithms.
16
Funding: $133.8M
Navidea Biopharmaceuticals has established a niche in precision medicine. The company focuses on the development and commercialization of diagnostic agents and therapeutics for cancer, autoimmune diseases, dementia, and movement disorders.
Navidea Biopharmaceuticals has established a niche in precision medicine. The company focuses on the development and commercialization of diagnostic agents and therapeutics for cancer, autoimmune diseases, dementia, and movement disorders.
17
Funding: $110M
Atalanta Therapeutics is a biotechnology company pioneering new treatment options for neurodegenerative diseases by utilizing our proprietary RNA interference platform.
Atalanta Therapeutics is a biotechnology company pioneering new treatment options for neurodegenerative diseases by utilizing our proprietary RNA interference platform.
18
Funding: $41.3M
Rune Labs is a software and data platform for neuromodulation and brain therapies of the future.
Rune Labs is a software and data platform for neuromodulation and brain therapies of the future.
19
Funding: $30M
Constant Therapy is developing a mobile app designed to provide therapy to patients who have traumatic brain injury, stroke, aphasia, and learning disabilities.
Constant Therapy is developing a mobile app designed to provide therapy to patients who have traumatic brain injury, stroke, aphasia, and learning disabilities.
20
Funding: $24.7M
Altoida Medical Device (AMD) provides health care professionals objective measurements of cognitive performance.
Altoida Medical Device (AMD) provides health care professionals objective measurements of cognitive performance.
21
Funding: $18.4M
NeuroSigma is a life sciences company focused on bioelectronics products and commercialization of its unique Trigeminal Nerve Stimulation (TNS) technology, and has a growing pipeline of treatments targeting epilepsy, depression, attention deficit hyperactivity disorder (ADHD), post-traumatic stress disorder (PTSD), Lennox Gastaut syndrome (LGS) and traumatic brain injury (TBI).
NeuroSigma is a life sciences company focused on bioelectronics products and commercialization of its unique Trigeminal Nerve Stimulation (TNS) technology, and has a growing pipeline of treatments targeting epilepsy, depression, attention deficit hyperactivity disorder (ADHD), post-traumatic stress disorder (PTSD), Lennox Gastaut syndrome (LGS) and traumatic brain injury (TBI).
22
Exploring the potential of cutting edge biomedical technology for human neuro-regeneration and neuro-reanimation. Our definitions of death, specifically the death of the human brain, may have to change in the very near future.
23
Funding: $14.4M
AgeneBio is developing innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function.
AgeneBio is developing innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function.
24
Funding: $11M
We provide physicians critical data for accelerating and expanding therapy while improving the diagnostic experience for patients with brain disorders.
We provide physicians critical data for accelerating and expanding therapy while improving the diagnostic experience for patients with brain disorders.
25
Funding: $7.7M
Cerebrotech Medical Systems develops novel technologies for the non-invasive monitoring of patients after strokes and brain injuries.
Cerebrotech Medical Systems develops novel technologies for the non-invasive monitoring of patients after strokes and brain injuries.
26
Funding: $250K
Convalesce is a therapeutic company enabling stem cell-based therapy for neurodegenerative conditions like Parkinson's, harnessing state-of-art biomaterials.
Convalesce is a therapeutic company enabling stem cell-based therapy for neurodegenerative conditions like Parkinson's, harnessing state-of-art biomaterials.